Regulation of clinical research sponsored by pharmaceutical companies: a proposal

Sotelo proposes that a third party, appointed by academic institutions, must be compulsorily placed between clinical researchers and drug companies.

Saved in:
Bibliographic Details
Published in:PLoS medicine 2006-07, Vol.3 (7), p.e306-e306
Main Author: Sotelo, Julio
Format: Article
Language:English
Subjects:
Academic Medicine
Bioethics
Clinical Pharmacology
Clinical trials
Commerce - economics
Commerce - legislation & jurisprudence
Conflict of Interest - legislation & jurisprudence
Corporate sponsorship
Costs
Councils
Drug Approval - economics
Drug Approval - legislation & jurisprudence
Drug Approval - organization & administration
Drug Costs
Drug Industry - economics
Drug Industry - legislation & jurisprudence
Ethical aspects
Ethics Committees, Research - legislation & jurisprudence
Ethics Committees, Research - organization & administration
FDA approval
Finance
Financing, Organized - legislation & jurisprudence
General Medicine
Humans
Influence
Marketing
Marketing - economics
Marketing - legislation & jurisprudence
Medical Ethics
Medical journals
Medical profession
Medical research
Mexico
Models, Theoretical
Motivation
Other
Periodicals as Topic - standards
Pharmaceutical industry
Pharmacology/Drug Discovery
Prescription drugs
Public interest
Publishing - standards
Randomized Controlled Trials as Topic - legislation & jurisprudence
Regulation
Research Methods
Research Support as Topic - legislation & jurisprudence
Review boards
Science Policy
Third party
Universities - organization & administration
Universities and colleges
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sotelo proposes that a third party, appointed by academic institutions, must be compulsorily placed between clinical researchers and drug companies.
ISSN:1549-1676
1549-1277
1549-1676
DOI:10.1371/journal.pmed.0030306